RE: So Undervalued21 Apr 2026 12:54
"We conservatively see fair value of the company at around 0.6p per share (market cap of ca.
£15m), which is derived from the Ox-1 and DAT programmes, and would expect that to be realised over
the next 12 months as the preclinical package for CT-010018 is delivered"
From todays Turner Pope research note